

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Zanidatamab is a bispecific antibody directed at which of the following targets?**
  - a. Two distinct HER2 domains**
  - b. HER2/HER3
  - c. PD-1/VEGF
  - d. CD3/HER2
- 2. Which of the following doses of cabozantinib is recommended for patients with Child-Pugh B liver function?**
  - a. 20 mg
  - b. 40 mg
  - c. 60 mg**
  - d. 100 mg
- 3. Which of the following adverse events is most commonly associated with FGFR inhibitors?**
  - a. Insomnia
  - b. Dry mouth
  - c. Cytokine release syndrome
  - d. Hyperphosphatemia**
- 4. What was the approximate response rate observed with trastuzumab deruxtecan in the cohort of patients with HER2-positive IHC 2+ or 3+ unresectable or recurrent biliary tract cancer in the Phase II HERB trial?**
  - a. Responses were not observed in this population
  - b. 16%
  - c. 36%**
  - d. Higher than 60%
- 5. Which of the following types of toxicity is most commonly observed in clinical studies of zanidatamab for patients with HER2-expressing biliary tract cancer?**
  - a. Dermatologic
  - b. Gastrointestinal**
  - c. Neurologic
  - d. Ocular